ISRCTN10942146已完成未知
A randomized double blind study to find out whether there is any difference in the efficacy and side effects of Endemali® and a combination of diloxanide furoate and metronidazole
Hamdard University (Pakistan)0 个研究点目标入组 202 人开始时间: 2012年7月30日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 202
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. All the confirmed cases of amoebiasis and between the ages of 5 and 60 years were invited to be included in the study
- •2. Willing to be assigned to any of the two treatment groups
排除标准
- •All those who had multiple problems
研究者
相似试验
进行中（未招募）
不适用
A Randomized, double blind study to determine the effect oftwo dose schedules of R1507 or placebo, both in combinationwith erlotinib (Tarceva), on progression-free survival inpatients with advanced non-small cell lung cancer with diseaseprogression after first or second line chemotherapy. - NDClinical stage IIIb/IV Non-small cell lung cancer with diseaseprogression following at least one but no more than two standardchemotherapy regimensMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBEUCTR2008-001736-12-ITROCHE150
进行中（未招募）
不适用
A Randomized, double blind study to determine the effect of two dose schedules ofR1507 or placebo, both in combination with erlotinib (Tarceva®), on progression-freesurvival in patients with advanced non-small cell lung cancer with disease progression after first or second line chemotherapyTo investigate in a randomized fashion if the addition of targeted IGF-1R blockade with R1507 has additional clinical benefit when combined with erlotinib in patients with advanced NSCLC who have failed at least one, but no more than two standard chemotherapy regimens. The study will also investigate 2 doses and schedules of R1507 combined with erlotinib compared with erlotinib and placebo, and assess the safety and tolerability of the combination in this patient population.MedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2008-001736-12-ATF. Hoffmann-La Roche Ltd150
进行中（未招募）
不适用
A Randomized, double blind study to determine the effect of two dose schedules ofR1507 or placebo, both in combination with erlotinib (Tarceva®), on progression-freesurvival in patients with advanced non-small cell lung cancer with disease progression after first or second line chemotherapyAdvanced (Stage IIIb/IV) Non Small Cell Lung Cancer patients who have failed at least one but no more than two standard chemotherapy regimens.MedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2008-001736-12-IEF. Hoffmann-La Roche Ltd150
进行中（未招募）
1 期
A Randomized, double blind study to determine the effect of two dose schedules ofR1507 or placebo, both in combination with erlotinib (Tarceva®), on progression-freesurvival in patients with advanced non-small cell lung cancer with disease progression after first or second line chemotherapyEUCTR2008-001736-12-FRF. Hoffmann-La Roche Ltd150
进行中（未招募）
1 期
A double-blind randomized study to determine the effect of empagliflozin versus placebo on brain insulin sensitivity in patients with prediabetesEUCTR2016-003477-18-DEniversity Hospital Tuebingen40